Eradication of HIV-1 from the macrophage reservoir: An uncertain goal?

Viruses

Volumn 7, Issue 4, 2015, Pages 1578-1598

  Abbas, Wasim ^a   Tariq, Muhammad ^a   Iqbal, Mazhar ^b   Kumar, Amit ^c   Herbein, Georges ^c  

^a LAHORE UNIVERSITY OF MANAGEMENT SCIENCES   (Pakistan)

^b NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^c Université Bourgogne Franche Comté   (France)

Author keywords

CART; HIV 1; Latency; Macrophage; Reservoirs

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS ISOLATION; HETEROZYGOTE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CARRIER STATE; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; VIRUS LATENCY;

EID: 84928952324     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7041578     Document Type: Review

References (158)

1. Maartens, G.; Celum, C.; Lewin, S.R. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. Lancet 2014, 384, 258-271.
2. Ruelas, D.S.; Greene, W.C. An integrated overview of HIV-1 latency. Cell 2013, 155, 519-529.
3. Anderson, J.L.; Fromentin, R.; Corbelli, G.M.; Østergaard, L.; Ross, A.L. Progress Towards an HIV Cure: Update from the 2014 International AIDS Society Symposium. AIDS Res. Hum. Retrovirus. 2015, 31, 36-44.
4. Walensky, R.P.; Paltiel, A.D.; Losina, E.; Mercincavage, L.M.; Schackman, B.R.; Sax, P.E.; Weinstein, M.C.; Freedberg, K.A. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 2006, 194, 11-19.
5. Perelson, A.S.; Essunger, P.; Cao, Y.; Vesanen, M.; Hurley, A.; Saksela, K.; Markowitz, M.; Ho, D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387, 188-191.
6. Murray, C.J.; Ortblad, K.F.; Guinovart, C.; Lim, S.S.; Wolock, T.M.; Roberts, D.A.; Dansereau, E.A.; Graetz, N.; Barber, R.M.; Brown, J.C., et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384, 1005-1070.
7. Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853-860.
8. Passaes, C.P.; Saez-Cirion, A. HIV cure research: Advances and prospects. Virology 2014, 454, 340-352.
9. Ho, Y.C.; Shan, L.; Hosmane, N.N.; Wang, J.; Laskey, S.B.; Rosenbloom, D.I.; Lai, J.; Blankson, J.N.; Siliciano, J.D.; Siliciano, R.F. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013, 155, 540-551.
10. Margolis, D.M. How might we cure HIV? Curr. Infect. Dis. Rep. 2014, 16, 392.
11. Deng, K.; Siliciano, R.F. HIV: Early treatment may not be early enough. Nature 2014, 512, 35-36.
12. Katlama, C.; Deeks, S.G.; Autran, B.; Martinez-Picado, J.; van Lunzen, J.; Rouzioux, C.; Miller, M.; Vella, S.; Schmitz, J.E.; Ahlers, J., et al. Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. Lancet 2013, 381, 2109-2117.
13. Richman, D.D.; Margolis, D.M.; Delaney, M.; Greene, W.C.; Hazuda, D.; Pomerantz, R.J. The challenge of finding a cure for HIV infection. Science 2009, 323, 1304-1307.
14. Archin, N.M.; Margolis, D.M. Emerging strategies to deplete the HIV reservoir. Curr. Opin. Infect. Dis. 2014, 27, 29-35.
15. Van Lint, C.; Bouchat, S.; Marcello, A. HIV-1 transcription and latency: An update. Retrovirology 2013, 10, e67.
16. Coiras, M.; Lopez-Huertas, M.R.; Perez-Olmeda, M.; Alcami, J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 2009, 7, 798-812.
17. Deeks, S.G.; Lewin, S.R.; Havlir, D.V. The end of AIDS: HIV infection as a chronic disease. Lancet 2013, 382, 1525-1533.
18. Zaikos, T.D.; Collins, K.L. Long-lived reservoirs of HIV-1. Trends Microbiol. 2014, 22, 173-175.
19. Hong, F.F.; Mellors, J.W. Changes in HIV reservoirs during long-term antiretroviral therapy. Curr. Opin. HIV AIDS 2015, 10, 43-48.
20. Svicher, V.; Ceccherini-Silberstein, F.; Antinori, A.; Aquaro, S.; Perno, C.F. Understanding HIV compartments and reservoirs. Curr. HIV/AIDS Rep. 2014, 11, 186-194.
21. Alexaki, A.; Liu, Y.; Wigdahl, B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 2008, 6, 388-400.
22. Ananworanich, J.; Dube, K.; Chomont, N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr. Opin. HIV AIDS 2015, 10, 18-28.
23. Abbas, W.; Herbein, G. Molecular understanding of HIV-1 latency. Adv. Virol. 2012, 9, e574967.
24. Siliciano, R.F. Opening fronts in HIV vaccine development: Targeting reservoirs to clear and cure. Nat. Med. 2014, 20, 480-481.
25. Colin, L.; van Lint, C. Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology 2009, 6, e111.
26. Kumar, A.; Abbas, W.; Herbein, G. HIV-1 latency in monocytes/macrophages. Viruses 2014, 6, 1837-1860.
27. Marcello, A. Latency: The hidden HIV-1 challenge. Retrovirology 2006, 3, e7.
28. Durand, C.M.; Blankson, J.N.; Siliciano, R.F. Developing strategies for HIV-1 eradication. Trends Immunol. 2012, 33, 554-562.
29. Pang, S.; Koyanagi, Y.; Miles, S.; Wiley, C.; Vinters, H.V.; Chen, I.S. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 1990, 343, 85-89.
30. Kelly, J.; Beddall, M.H.; Yu, D.; Iyer, S.R.; Marsh, J.W.; Wu, Y. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 2008, 372, 300-312.
31. Margolis, D.M. Mechanisms of HIV latency: An emerging picture of complexity. Curr. HIV/ AIDS Rep. 2010, 7, 37-43.
32. Cherrier, T.; le Douce, V.; Eilebrecht, S.; Riclet, R.; Marban, C.; Dequiedt, F.; Goumon, Y.; Paillart, J.C.; Mericskay, M.; Parlakian, A., et al. CTIP2 is a negative regulator of P-TEFb. Proc. Natl. Acad. Sci. USA 2013, 110, 12655-12660.
33. Eilebrecht, S.; le Douce, V.; Riclet, R.; Targat, B.; Hallay, H.; van Driessche, B.; Schwartz, C.; Robette, G.; van Lint, C.; Rohr, O., et al. HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters. Nucleic Acids Res. 2014, 42, 4962-4971.
34. Eilebrecht, S.; Schwartz, C.; Rohr, O. Non-coding RNAs: Novel players in chromatin-regulation during viral latency. Curr. Opin. Virol. 2013, 3, 387-393.
35. Al-Harthi, L.; Kashanchi, F. Mechanisms of HIV-1 latency post HAART treatment area. Curr. HIV Res. 2011, 9, 552-553.
36. Carpio, L.; Klase, Z.; Coley, W.; Guendel, I.; Choi, S.; van Duyne, R.; Narayanan, A.; Kehn-Hall, K.; Meijer, L.; Kashanchi, F. MicroRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. J. RNAi Gene Silenc. 2010, 6, 386-400.
37. Le Douce, V.; Herbein, G.; Rohr, O.; Schwartz, C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 2010, 7, e32.
38. Smith, P.D.; Meng, G.; Salazar-Gonzalez, J.F.; Shaw, G.M. Macrophage HIV-1 infection and the gastrointestinal tract reservoir. J. Leukoc. Biol. 2003, 74, 642-649.
39. Veazey, R.S.; deMaria, M.; Chalifoux, L.V.; Shvetz, D.E.; Pauley, D.R.; Knight, H.L.; Rosenzweig, M.; Johnson, R.P.; Desrosiers, R.C.; Lackner, A.A. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280, 427-431.
40. Herbein, G.; Gras, G.; Khan, K.A.; Abbas, W. Macrophage signaling in HIV-1 infection. Retrovirology 2010, 7, e34.
41. Kumar, A.; Abbas, W.; Herbein, G. TNF and TNF receptor superfamily members in HIV infection: New cellular targets for therapy? Mediators Inflamm. 2013, 2013, e484378.
42. Campbell, J.H.; Hearps, A.C.; Martin, G.E.; Williams, K.C.; Crowe, S.M. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 2014, 28, 2175-2187.
43. Watters, S.A.; Mlcochova, P.; Gupta, R.K. Macrophages: The neglected barrier to eradication. Curr. Opin. Infect. Dis. 2013, 26, 561-566.
44. Kumar, A.; Herbein, G. The macrophage: A therapeutic target in HIV-1 infection. Mol. Cell. Ther. 2014, 2, e10.
45. Zhu, T.; Muthui, D.; Holte, S.; Nickle, D.; Feng, F.; Brodie, S.; Hwangbo, Y.; Mullins, J.I.; Corey, L. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 2002, 76, 707-716.
46. Lambotte, O.; Taoufik, Y.; de Goer, M.G.; Wallon, C.; Goujard, C.; Delfraissy, J.F. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2000, 23, 114-119.
47. McElrath, M.J.; Steinman, R.M.; Cohn, Z.A. Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J. Clin. Invest. 1991, 87, 27-30.
48. Kulkosky, J.; Bray, S. HAART-persistent HIV-1 latent reservoirs: Their origin, mechanisms of stability and potential strategies for eradication. Curr. HIV Res.2006, 4, 199-208.
49. Cribbs, S.K.; Lennox, J.; Caliendo, A.M.; Brown, L.A.; Guidot, D.M. Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. AIDS Res. Hum. Retrovirus. 2015, 31, 64-70.
50. Thieblemont, N.; Weiss, L.; Sadeghi, H.M.; Estcourt, C.; Haeffner-Cavaillon, N. CD14lowCD16high: A cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur. J. Immunol. 1995, 25, 3418-3424.
51. Sonza, S.; Mutimer, H.P.; Oelrichs, R.; Jardine, D.; Harvey, K.; Dunne, A.; Purcell, D.F.; Birch, C.; Crowe, S.M. Monocytes harbour replication-competent non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001, 15, 17-22.
52. Ellery, P.J.; Tippett, E.; Chiu, Y.L.; Paukovics, G.; Cameron, P.U.; Solomon, A.; Lewin, S.R.; Gorry, P.R.; Jaworowski, A.; Greene, W.C., et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 2007, 178, 6581-6589.
53. Kim, W.K.; Sun, Y.; Do, H.; Autissier, P.; Halpern, E.F.; Piatak, M., Jr.; Lifson, J.D.; Burdo, T.H.; McGrath, M.S.; Williams, K. Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage. J. Leukoc. Biol. 2010, 87, 557-567.
54. Crowe, S.M.; Ziegler-Heitbrock, L. Editorial: Monocyte subpopulations and lentiviral infection. J. Leukoc. Biol. 2010, 87, 541-543.
55. Ansari, A.W.; Meyer-Olson, D.; Schmidt, R.E. Selective expansion of pro-inflammatory chemokine CCL2-loaded CD14+CD16+ monocytes subset in HIV-infected therapy naive individuals. J. Clin. Immunol. 2013, 33, 302-306.
56. Ansari, A.W.; Heiken, H.; Meyer-Olson, D.; Schmidt, R.E. CCL2: A potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur. J. Immunol. 2011, 41, 3412-3418.
57. Cinque, P.; Vago, L.; Mengozzi, M.; Torri, V.; Ceresa, D.; Vicenzi, E.; Transidico, P.; Vagani, A.; Sozzani, S.; Mantovani, A., et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998, 12, 1327-1332.
58. Vicenzi, E.; Alfano, M.; Ghezzi, S.; Gatti, A.; Veglia, F.; Lazzarin, A.; Sozzani, S.; Mantovani, A.; Poli, G. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: Suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J. Leukoc. Biol. 2000, 68, 405-412.
59. Coquillard, G.; Patterson, B.K. Determination of hepatitis C virus-infected monocyte lineage reservoirs in individuals with or without HIV coinfection. J. Infect. Dis. 2009, 200, 947-954.
60. Dichamp, I.; Abbas, W.; Kumar, A.; di Martino, V.; Herbein, G. Cellular activation and intracellular HCV load in peripheral blood monocytes isolated from HCV monoinfected and HIV-HCV coinfected patients. PLOS ONE 2014, 9, e96907.
61. Mills, C.D.; Ley, K. M1 and M2 macrophages: The chicken and the egg of immunity. J. Innate Immun. 2014, 6, 716-726.
62. Xuan, W.; Qu, Q.; Zheng, B.; Xiong, S.; Fan, G.H. The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J. Leukoc. Biol. 2015, 97, 61-69.
63. Cassol, E.; Cassetta, L.; Alfano, M.; Poli, G. Macrophage polarization and HIV-1 infection. J. Leukoc. Biol. 2010, 87, 599-608.
64. Herbein, G.; Varin, A. The macrophage in HIV-1 infection: From activation to deactivation? Retrovirology 2010, 7, e33.
65. Italiani, P.; Boraschi, D. From monocytes to M1/M2 macrophages: Phenotypical versus functional differentiation. Front. Immunol. 2014, 5, e514.
66. Herbein, G.; Khan, K.A. Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol. 2008, 29, 61-67.
67. Clerici, M.; Shearer, G.M. A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol. Today 1993, 14, 107-111.
68. Crowe, S.; Zhu, T.; Muller, W.A. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J. Leukoc. Biol. 2003, 74, 635-641.
69. Zhu, T. HIV-1 in peripheral blood monocytes: An underrated viral source. J. Antimicrob. Chemother. 2002, 50, 309-311.
70. Kedzierska, K.; Crowe, S.M. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr. Med. Chem. 2002, 9, 1893-1903.
71. Stevenson, M. Role of myeloid cells in HIV-1-host interplay. J. Neurovirol. 2014, doi:10.1007/s13365-014-0281-3.
72. Spivak, A.M.; Salgado, M.; Rabi, S.A.; O’Connell, K.A.; Blankson, J.N. Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J. Virol. 2011, 85, 10399-10403.
73. Schuitemaker, H.; Kootstra, N.A.; de Goede, R.E.; de Wolf, F.; Miedema, F.; Tersmette, M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 1991, 65, 356-363.
74. Gendelman, H.E.; Orenstein, J.M.; Martin, M.A.; Ferrua, C.; Mitra, R.; Phipps, T.; Wahl, LA.; Lane, H.C.; Fauci, A.S.; Burke, D.S., et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 1988, 167, 1428-1441.
75. Gartner, S.; Markovits, P.; Markovitz, D.M.; Betts, R.F.; Popovic, M. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 1986, 256, 2365-2371.
76. Koyanagi, Y.; Miles, S.; Mitsuyasu, R.T.; Merrill, J.E.; Vinters, H.V.; Chen, I.S. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987, 236, 819-822.
77. Llewellyn, N.; Zioni, R.; Zhu, H.; Andrus, T.; Xu, Y.; Corey, L.; Zhu, T. Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: Genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. J. Leukoc. Biol. 2006, 80, 1118-1126.
78. Fulcher, J.A.; Hwangbo, Y.; Zioni, R.; Nickle, D.; Lin, X.; Heath, L.; Mullins, J.I.; Corey, L.; Zhu, T. Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J. Virol. 2004, 78, 7883-7893.
79. Xu, Y.; Zhu, H.; Wilcox, C.K.; van’t Wout, A.; Andrus, T.; Llewellyn, N.; Stamatatos, L.; Mullins, J.I.; Corey, L.; Zhu, T. Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus. J. Infect. Dis. 2008, 197, 309-318.
80. Valcour, V.G.; Shiramizu, B.T.; Shikuma, C.M. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J. Leukoc. Biol. 2010, 87, 621-626.
81. Caselli, E.; Galvan, M.; Cassai, E.; Caruso, A.; Sighinolfi, L.; di Luca, D. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood 2005, 106, 2790-2797.
82. Orenstein, J.M.; Fox, C.; Wahl, S.M. Macrophages as a source of HIV during opportunistic infections. Science 1997, 276, 1857-1861.
83. Qi, X.; Koya, Y.; Saitoh, T.; Saitoh, Y.; Shimizu, S.; Ohba, K.; Yamamoto, N.; Yamaoka, S.; Yamamoto, N. Efficient induction of HIV-1 replication in latently infected cells through contact with CD4+ T cells: Involvement of NF-kappaB activation. Virology 2007, 361, 325-334.
84. Baxter, A.E.; Russell, R.A.; Duncan, C.J.; Moore, M.D.; Willberg, C.B.; Pablos, J.L.; Finzi, A.; Kaufmann, D.E.; Ochsenbauer, C.; Kappes, J.C., et al. Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. Cell Host Microbe 2014, 16, 711-721.
85. Kugelberg, E. Macrophages: Capturing HIV-infected T cells. Nat. Rev. Immunol. 2015, 15, 2-3.
86. Carter, C.A.; Ehrlich, L.S. Cell biology of HIV-1 infection of macrophages. Annu. Rev. Microbiol. 2008, 62, 425-443.
87. Jones, G.; Power, C. Regulation of neural cell survival by HIV-1 infection. Neurobiol. Dis. 2006, 21, 1-17.
88. McNelis, J.C.; Olefsky, J.M. Macrophages, immunity, and metabolic disease. Immunity 2014, 41, 36-48.
89. Coleman, C.M.; Wu, L. HIV interactions with monocytes and dendritic cells: Viral latency and reservoirs. Retrovirology 2009, 6, e51.
90. Fischer, T.; Wyatt, C.M.; D’Agati, V.D.; Croul, S.; McCourt, L.; Morgello, S.; Rappaport, J. Mononuclear phagocyte accumulation in visceral tissue in HIV encephalitis: Evidence for increased monocyte/macrophage trafficking and altered differentiation. Curr. HIV Res. 2014, 12, 201-212.
91. Tavazzi, E.; Morrison, D.; Sullivan, P.; Morgello, S.; Fischer, T. Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection. Curr. HIV Res. 2014, 12, 97-110.
92. Reynoso, R.; Minces, L.; Salomon, H.; Quarleri, J. HIV-1 infection downregulates nuclear telomerase activity on lymphoblastoic cells without affecting the enzymatic components at the transcriptional level. AIDS Res. Hum. Retrovirus. 2006, 22, 425-429.
93. Franzese, O.; Adamo, R.; Pollicita, M.; Comandini, A.; Laudisi, A.; Perno, C.F.; Aquaro, S.; Bonmassar, E. Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4+ T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). J. Med. Virol. 2007, 79, 639-646.
94. Ballon, G.; Ometto, L.; Righetti, E.; Cattelan, A.M.; Masiero, S.; Zanchetta, M.; Chieco-Bianchi, L.; de Ross, I.A. Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. J. Infect. Dis. 2001, 183, 417-424.
95. Lichterfeld, M.; Mou, D.; Cung, T.D.; Williams, KL.; Waring, M.T.; Huang, J.; Pereyra, F.; Trocha, A.; Freeman, G.J.; Rosenberg, E.S., et al. Telomerase activity of HIV-1-specific CD8+ T cells: Constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 2008, 112, 3679-3687.
96. Ojeda, D.; Lopez-Costa, J.J.; Sede, M.; López, E.M.; Berria, M.I.; Quarleri, J. Increased in vitro glial fibrillary acidic protein expression, telomerase activity, and telomere length after productive human immunodeficiency virus-1 infection in murine astrocytes. J. Neurosci. Res. 2014, 92, 267-274.
97. Osman, A.; Bhuyan, F.; Hashimoto, M.; Nasser, H.; Maekawa, T.; Suzu, S. M-CSF inhibits anti-HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages. J. Immunol. 2014, 192, 5083-5089.
98. Swingler, S.; Brichacek, B.; Jacque, J.M.; Ulich, C.; Zhou, J.; Stevenson, M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424, 213-219.
99. Geleziunas, R.; Xu, W.; Takeda, K.; Ichijo, H.; Greene, W.C. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001, 410, 834-838.
100. Mahlknecht, U.; Deng, C.; Lu, M.C.; Greenough, T.C.; Sullivan, J.L.; O’Brien, W.A.; Herbein, G. Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: Role for Nef and immune activation in viral persistence. J. Immunol. 2000, 165, 6437-6446.
101. Oyaizu, N.; McCloskey, T.W.; Coronesi, M.; Chirmule, N.; Kalyanaraman, V.S.; Pahwa, S. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 1993, 82, 3392-3400.
102. Badley, A.D.; McElhinny, J.A.; Leibson, P.J.; Lynch, D.H.; Alderson, M.R.; Paya, C.V. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J. Virol. 1996, 70, 199-206.
103. Badley, A.D.; Dockrell, D.; Simpson, M.; Schut, R.; Lynch, D.H.; Leibson, P.; Paya, C.V. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 1997, 185, 55-64.
104. Grell, M.; Douni, E.; Wajant, H.; Löhden, M.; Clauss, M.; Maxeiner, B.; Georgopoulos, S.; Lesslauer, W.; Kollias, G.; Pfizenmaier, K., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83, 793-802.
105. Zheng, L.; Fisher, G.; Miller, R.E.; Peschon, J.; Lynch, D.H.; Lenardo, M.J. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377, 348-351.
106. Lahdevirta, J.; Maury, C.P.; Teppo, A.M.; Repo, H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am. J. Med. 1988, 85, 289-291.
107. Yang, Y.; Tikhonov, I.; Ruckwardt, T.J.; Djavani, M.; Zapata, J.C.; Pauza, C.D.; Salvato, M.S. Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4+ cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J. Virol. 2003, 77, 6700-6708.
108. Herbein, G.; Mahlknecht, U.; Batliwalla, F.; Gregersen, P.; Pappas, T.; Butler, J.; O’Brien, W.A.; Verdin, E. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395, 189-194.
109. Crowe, S.M.; Mills, J.; Elbeik, T.; Lifson, J.D.; Kosek, J.; Marshall, J.A.; Engleman, E.G.; McGrath, M.S. Human immunodeficiency virus-infected monocyte-derived macrophages express surface gp120 and fuse with CD4 lymphoid cells in vitro: A possible mechanism of T lymphocyte depletion in vivo. Clin. Immunol. Immunopathol. 1992, 5, 143-151.
110. Crowe, S.M.; Mills, J.; Kirihara, J.; Boothman, J.; Marshall, J.A.; McGrath, M.S. Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res. Hum. Retrovirus. 1990, 6, 1031-1037.
111. Peressin, M.; Proust, A.; Schmidt, S.; Su, B.; Lambotin, M.; Biedma, M.E.; Laumond, G.; Decoville, T.; Holl, V.; Moog, C. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. AIDS 2014, 28, 667-677.
112. Duncan, C.J.; Williams, J.P.; Schiffner, T.; Gärtner, K.; Ochsenbauer, C.; Kappes, J.; Russell, R.A.; Frater, J.; Sattentau, Q.J. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J. Virol. 2014, 8, 2025-2034.
113. Fantuzzi, L.; Belardelli, F.; Gessani, S. Monocyte/macrophage-derived CC chemokines and their modulation by HIV-1 and cytokines: A complex network of interactions influencing viral replication and AIDS pathogenesis. J. Leukoc. Biol. 2003, 74, 719-725.
114. Mengozzi, M.; de Filippi, C.; Transidico, P. Biswas, P.; Cota, M.; Ghezzi, S.; Vicenzi, E.; Mantovani, A.; Sozzani, S.; Poli, G. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 1999, 93, 1851-1857.
115. Schmidtmayerova, H.; Nottet, H.S.; Nuovo, G.; Raabe, T.; Flanagan, C.R.; Dubrovsky, L.; Gendelman, H.E.; Cerami, A.; Bukrinsky, M.; Sherry, B. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proc. Natl. Acad. Sci. USA 1996, 93, 700-704.
116. Swingler, S.; Mann, A.; Jacque, J.; Brichacek, B.; Sasseville, V.G.; Williams, K.; Lackner, A.A.; Janoff, E.N.; Wang, R.; Fisher, D., et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat. Med. 1999, 5, 997-1003.
117. Liu, X.; Shah, A.; Gangwani, M.R.; Silverstein, P.S.; Fu, M.; Kumar, A. HIV-1 Nef induces CCL5 production in astrocytes through p38-MAPK and PI3K/Akt pathway and utilizes NF-kB, CEBP and AP-1 transcription factors. Sci. Rep. 2014, 4, 4450.
118. Verollet, C.; Souriant, S.; Bonnaud, E.; Jolicoeur, P.; Raynaud-Messina, B.; Kinnaer, C.; Fourquaux, I.; Imle, A.; Benichou, S.; Fackler, O.T., et al. HIV-1 reprograms the migration of macrophages. Blood 2015, 125, 1611-1622.
119. Mangino, G.; Percario, Z.A.; Fiorucci, G.; Vaccari, G.; Acconcia, F.; Chiarabelli, C.; Leone, S.; Noto, A.; Horenkamp, F.A.; Manrique, S., et al. HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: Involvement of TNF alpha receptor associated factor 2. PLOS ONE 2011, 6, e22982.
120. Perno, C.F.; Newcomb, F.M.; Davis, D.A.; Aquaro, S.; Humphrey, R.W.; Caliò, R.; Yarchoan, R. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 1998, 178, 413-422.
121. Gavegnano, C.; Detorio, M.A.; Bassit, L.; Hurwitz, S.J.; North, T.W.; Schinazi, R.F. Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. Antimicrob. Agents Chemother. 2013, 57, 1262-1269.
122. McQuade, T.J.; Tomasselli, A.G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T.K.; Heinrikson, R.L.; Tarpley, W.G. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 1990, 247, 454-456.
123. Adachi, M.; Ohhara, T.; Kurihara, K.; Tamada, T.; Honjo, E.; Okazaki, N.; Arai, S.; Shoyama, Y.; Kimura, K.; Matsumura, H., et al. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc. Natl. Acad. Sci. USA 2009, 106, 4641-4646.
124. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.; Roden, D.M.; Wilkinson, G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101, 289-294.
125. Zastre, J.A.; Chan, G.N.; Ronaldson, P.T.; Ramaswamy, M.; Couraud, P.O.; Romero, I.A.; Weksler, B.; Bendayan, M.; Bendayan, R. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 2009, 87, 1023-1036.
126. Robillard, K.R.; Chan, G.N.; Zhang, G.; la Porte, C.; Cameron, W.; Bendayan, R. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob. Agents Chemother. 2014, 58, 1713-1722.
127. Srinivas, R.V.; Middlemas, D.; Flynn, P.; Fridland, A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. 1998, 42, 3157-3162.
128. Jorajuria, S.; Dereuddre-Bosquet, N.; Becher, F, Martin, S.; Porcheray, F.; Garrigues, A.; Mabondzo, A.; Benech, H.; Grassi, J.; Orlowski, S., et al. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir. Ther. 2004, 9, 519-528.
129. Choo, E.F.; Leake, B.; Wandel, C.; Imamura, H.; Wood, A.J.; Wilkinson, G.R.; Kim, R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 2000, 28, 655-660.
130. Zha, W.; Wang, G.; Xu, W.; Liu, X.; Wang, Y.; Zha, B.S.; Shi, J.; Zhao, Q.; Gerk, P.M.; Studer, E., et al. Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages. PLOS ONE 2013, 8, e54349.
131. Igarashi, T.; Brown, C.R.; Endo, Y.; Buckler-White, A.; Plishka, R.; Bischofberger, N.; Hirsch, V.; Martin, M.A. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 2001, 98, 658-663.
132. Marsden, M.D.; Avancena, P.; Kitchen, C.M.; Hubbard, T.; Zack, J.A. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob. Agents Chemother. 2011, 55, 3696-3702.
133. Micci, L.; Alvarez, X.; Iriele, R.I.; Ortiz, A.M.; Ryan, E.S.; McGary, C.S.; Deleage, C.; McAtee, B.B.; He, T.; Apetrei, C., et al. CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. PLOS Pathog. 2014, 10, e1004467.
134. Adamson, C.S.; Freed, E.O. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 2010, 85, 119-141.
135. Hrecka, K.; Hao, C.; Gierszewska, M.; Swanson, S.K.; Kesik-Brodacka, M.; Srivastava, S.; Florens, L.; Washburn, M.P.; Skowronski, J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474, 658-661.
136. Lahouassa, H.; Daddacha, W.; Hofmann, H.; Ayinde, D.; Logue, E.C.; Dragin, L.; Bloch, N.; Maudet, C.; Bertrand, M.; Gramberg, T., et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 2012, 13, 223-228.
137. Kyei, G.B.; Cheng, X.; Ramani, R.; Ratner, L. Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. Cell Host Microbe 2015, 17, 98-106.
138. Allouch, A.; David, A.; Amie, S.M.; Lahouassa, H.; Chartier, L.; Margottin-Goguet, F.; Barré-Sinoussi, F.; Kim, B.; Sáez-Cirión, A.; Pancino, G. p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc. Natl. Acad. Sci. USA 2013, 110, E3997-E4006.
139. Sheehy, A.M.; Gaddis, N.C.; Choi, J.D.; Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418, 646-650.
140. Peng, G.; Lei, K.J.; Jin, W.; Greenwell-Wild, T.; Wahl, S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 2006, 203, 41-46.
141. Berger, G.; Durand, S.; Fargier, G.; Nguyen, X.N.; Cordeil, S.; Bouaziz, S.; Muriaux, D.; Darlix, J.L.; Cimarelli, A. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLOS Pathog. 2011, 7, e1002221.
142. Sabbatucci, M.; Covino, D.A.; Purificato, C.; Mallano, A.; Federico, M.; Lu, J.; Rinaldi, A.O.; Pellegrini, M.; Bona, R.; Michelini, Z., et al. Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology 2015, 12, e4.
143. Vicenzi, E.; Poli, G. Novel factors interfering with human immunodeficiency virus-type 1 replication in vivo and in vitro. Tissue Antigens 2013, 81, 61-71.
144. Neil, S.J.; Zang, T.; Bieniasz, P.D. Tetherin inhibits retrovirus release and isantagonized by HIV-1 Vpu. Nature 2008, 451, 425-430.
145. Van Damme, N.; Goff, D.; Katsura, C.; Jorgenson, R.L.; Mitchell, R.; Johnson, M.C.; Stephens, E.B.; Guatelli, J. The interferon-induced protein BST-2 restricts HIV-1 releaseand is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3, 245-252.
146. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5a restricts HIV-1infection in old world monkeys. Nature 2004, 427, 848-853.
147. Goujon, C.; Moncorgé, O.; Bauby, H.; Doyle, T.; Ward, C.C.; Schaller, T.; Hué, S.; Barclay, W.S.; Schulz, R.; Malim, M.H. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 502, 559-562.
148. Siliciano, R.F.; Greene, W.C. HIV latency. Cold Spring Harb. Perspect. Med. 2011, 1, a007096.
149. Barr, S.D.; Ciuffi, A.; Leipzig, J.; Shinn, P.; Ecker, J.R.; Bushman, F.D. HIV integration site selection: Targeting in macrophages and the effects of different routes of viral entry. Mol. Ther. 2006, 14, 218-225.
150. Killebrew, D.A.; Troelstrup, D.; Shiramizu, B. Preferential HIV-1 integration sites in macrophages and HIV-associated malignancies. Cell. Mol. Biol. 2004, 50, OL581-OL589.
151. Arfi, V.; Riviere, L.; Jarrosson-Wuilleme, L.; Goujon, C.; Rigal, D.; Darlix, J.L.; Cimarelli, A. Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J. Virol. 2008, 82, 6557-6565.
152. Harrold, S.M.; Wang, G.; McMahon, D.K.; Riddler, S.A.; Mellors, J.W.; Becker, J.T.; Caldararo, R.; Reinhart, T.A.; Achim, C.L.; Wiley, C.A. Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy. AIDS Res. Hum. Retrovirus. 2002, 18, 427-434.
153. Rasmussen, T.A.; Schmeltz Søgaard, O.; Brinkmann, C.; Wightman, F.; Lewin, S.R.; Melchjorsen, J.; Dinarello, C.; Østergaard, L.; Tolstrup, M. Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Hum. Vaccin. Immunother. 2013, 9, 13-21.
154. Banerjee, C.; Archin, N.; Michaels, D.; Belkina, A.C.; Denis, G.V.; Bradner, J.; Sebastiani, P.; Margolis, D.M.; Montano, M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J. Leukoc. Biol. 2012, 92, 1147-1154.
155. Kraft-Terry, S.D.; Stothert, A.R.; Buch, S.; Gendelman, H.E. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol. Dis. 2010, 37, 542-548.
156. Koppensteiner, H.; Brack-Werner, R.; Schindler, M. Macrophages and their relevance in human immunodeficiency virus type 1 infection. Retrovirology 2012, 9, e82.
157. Montaner, L.J.; Griffin, P.; Gordon, S. Interleukin 10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro. J. Gen. Virol. 1994, 75, 3393-3400.
158. Brown, A.; Zhang, H.; Lopez, P.; Pardo, C.A.; Gartner, S. In vitro modeling of the HIV-macrophage reservoir. J. Leukoc. Biol. 2006, 80, 1127-1135.